Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Genitourinary tumours, prostate

2628 - LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)


21 Oct 2018


Poster Discussion session - Genitourinary tumours, prostate


Cytotoxic Therapy

Tumour Site

Prostate Cancer


Nubaki Matsubara


Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284


N. Matsubara1, K.N. Chi2, M. Ozguroglu3, A. Rodriguez Antolin4, S. Feyerabend5, L. Fein6, B.Y. Alekseev7, G. Sulur8, A. Protheroe9, S. Li10, S.D. Mundle11, P. De Porre12, N. Tran13, K. Fazazi14

Author affiliations

  • 1 Division Oncology And Hematology, National Cancer Center Hospital East, 277-8577577 - Kashiwa, Chiba/JP
  • 2 Medical Oncology, British Columbia Cancer Agency, V5Z 4E6 - Vancouver/CA
  • 3 Medical Oncology, University Of Istanbul Cerrahpasa Medical Faculty, 34098 - Istanbul/TR
  • 4 Urology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 5 Urology, University of Tübingen, Tübingen/DE
  • 6 Clinical research In Oncology, Institute of Oncology Rosario, Rosario/AR
  • 7 Medical Sciences, Herzen Cancer Research Institute, 125284 - Moscow/RU
  • 8 Wc Clinical Oncology, Janssen R&D US, Los Angeles/US
  • 9 Medical Oncology, Churchill Hospital University of Oxford, OX3 7LE - Oxford/GB
  • 10 R&d, Janssen Research & Development, 90024 - Los Angeles/US
  • 11 Global Medical Affairs, Janssen Research & Development, 08869 - Raritan/US
  • 12 Be Clinical Oncology, Janssen R&D BE, Beerse/BE
  • 13 Clinical Oncology, Janssen R&D, 90024 - Los Angeles/US
  • 14 Medical Oncology, Institut Gustave Roussy, 94805 - Villejuif/FR

Abstract 2628


The randomized, double-blind, active-controlled LATITUDE study found that AAP + ADT significantly improved the primary end points, OS and rPFS vs ADT+PBO in patients with high risk mHSPC. Post hoc analyses were performed to assess correlation of PSA response with OS and rPFS.


597 men received ADT+AAP and 602 received ADT+PBO. PSA response (confirmed) was based on PCWG2 criteria. Hazard ratios (HR) between treatment arms were determined using Cox proportional-hazards model. Kendall’s tau was used to evaluate correlations.


The overall median (med) baseline PSA was 23.85 ng/mL (range 0.0; 8889.6). Addition of AAP to ADT improved all PSA parameters. Patients receiving AAP were significantly more likely to achieve 50% PSA response (Relative Risk (RR): 1.36) and 90% PSA response (RR: 2.30) vs PBO. Compared to nonresponders, the 50% and 90% PSA response to AAP reduced the risk of death by ≈56% and ≈89% (HR: 0.435 and 0.107, respectively), and by ≈41% and ≈72% (HR: 0.590 and 0.283 respectively) with PBO. A similar effect was noted on rPFS. Further, ADT+AAP demonstrated increasing potential of attaining PSA <0.2 ng/mL at 3, 6 and 12 months (RR: 5.15, 6.35, 6.33, respectively). In the ADT+AAP group, 58% patients reached PSA <0.2 vs 12.8% with PBO. The med time to PSA nadir was 6.4 mo and 3.8 mo in the ADT+AAP and the ADT+PBO groups, respectively. The significantly prolonged med time to PSA nadir in the ADT+AAP group (HR:0.644) was accompanied by a markedly deeper med nadir PSA value (AAP:0.09 ng/mL [range 0.02; 1269.79] vs PBO:2.36 ng/mL [range 0.02; 2254.50]). Lastly, AAP significantly delayed med time to PSA progression as compared to PBO (33.2 mo vs 7.4 mo, respectively; HR: 0.3, p < 0.0001) and the time to PSA progression strongly correlated with rPFS (Kendall’s tau = 0.9211) and OS (Kendall’s tau = 0.666).


Treatment of high-risk mHSPC with ADT+AAP demonstrates a significant depth of PSA response that strongly correlates with long-term outcomes of rPFS and OS.

Clinical trial identification


Legal entity responsible for the study

Janssen Research and Development.


Janssen Research and Development.

Editorial Acknowledgement

Editorial assistance for this poster was provided by Ann C Sherwood, PhD, and editorial assistance was funded by Janssen Research and Development.


K.N. Chi: Institutional funding: Janssen for the study; Grant funding: Astellas, Bayer, Sanofi Janssen; Personal fees: Astellas, Bayer, Sanofi, Essa, Roche. M. Ozguroglu: Honoraria: Janssen, Sanofi. A. Rodriguez Antolin: Consulting services, Expert testimony: Astellas, Bayer, Janssen. S. Feyerabend: Advisory boards: Janssen, Boehringer Ingelheim Pharma, Aventis, Honorarium: Janssen, Travel and accommodation expenses: Aventis. L. Fein: Grant support, Personal fees: Novartis, Pfizer, Roche, Merck, Merck Sharp & Dohme; Grant support: Janssen, AbbVie. B.Y. Alekseev: Personal fees: Janssen, Pfizer, Merck, Roche, Sanofi. A. Protheroe: Consulting, Advisory roles, Travel, accommodations, and expenses: Ipsen, Bayer, Roche, Bristol-Myers Squibb, Merck; Research funding: Merck. G. Sulur, S. Li, P. De Porre, N. Tran, S.D. Mundle: Employee, Stock Owner: Janssen Research & Development. K. Fazazi: Advisory boards; Honoraria: Janssen, Astellas, Sanofi, and Bayer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.